# CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

> **NCT01746992** · PHASE4 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 200 (estimated)

## Conditions studied

- ALK-negative Anaplastic Large Cell Lymphoma
- Peripherial T Cell Lymphoma,Not Otherwise Specified
- Angioimmunoblastic T Cell Lymphoma
- Enteropathy Associated T Cell Lymphoma
- Hepatosplenic T Cell Lymphoma
- Subcutaneous Panniculitis Like T Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide 750mg/m2
- **DRUG:** Vincristine 1.4mg/m2
- **DRUG:** Doxorubicin 50mg/m2
- **DRUG:** prednisone 60mg/m2
- **DRUG:** ifosfamide 2000mg/m2
- **DRUG:** pirarubicin 50mg/m2
- **DRUG:** pirarubicin 25mg/m2
- **DRUG:** Etoposide phosphate 100mg/m2
- **DRUG:** methotrexate 1500mg/m2

## Key facts

- **NCT ID:** NCT01746992
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2018-09
- **Final completion:** 2018-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01746992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01746992, "CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01746992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*